spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  BrainStorm Cell Therapeutics 

 HSMN NewsFeed - 26 Jun 2024
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn(R) Clinical Trial
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 20 Jun 2024
BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer
Regenerative Medicine Personnel
 HSMN NewsFeed - 23 Feb 2024
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn(R) in ALS
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 24 Oct 2023
BrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn(R) for the Treatment of ALS
Regenerative Medicine Neurology
 HSMN NewsFeed - 18 Oct 2023
BrainStorm Cell Therapeutics to Meet with US FDA to Discuss Development Plan for NurOwn as a Treatment of ALS
Regenerative Medicine Neurology
 HSMN NewsFeed - 12 Jul 2023
BrainStorm Cell Therapeutics Appoints Bob Dagher, M.D., as Executive Vice President and Chief Development Officer
Regenerative Medicine Personnel
 HSMN NewsFeed - 27 Mar 2023
BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review Biologics License Application for NurOwn(R) for the Treatment of ALS
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 27 Dec 2022
BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn(R)
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 10 Nov 2022
BrainStorm Cell Therapeutics Receives Refusal to File Letter from FDA for its New Biologics License Application for NurOwn for the treatment of ALS
Biopharmaceuticals Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 15 Sep 2022
BrainStorm Cell Therapeutics Announces Peer Reviewed Publication of Results from the NurOwn(R) Phase 2 Progressive MS Trial in Multiple Sclerosis Journal
Regenerative Medicine Neurology
 HSMN NewsFeed - 27 Dec 2021
FDA Authorizes Further NurOwn(R) Dosing Under Expanded Access Program
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 8 Nov 2021
BrainStorm Cell Therapeutics Expands Leadership Team to Support Clinical Development and Medical Affairs
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 14 Dec 2020
BrainStorm Announces NurOwn(R) Expanded Access Program
Regenerative Medicine Neurology Product Launch
 HSMN NewsFeed - 23 Nov 2020
BrainStorm to present NurOwn(R) Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND
Regenerative Medicine Neurology
 HSMN NewsFeed - 17 Nov 2020
BrainStorm Announces Topline Results from NurOwn(R) Phase 3 ALS Study
Regenerative Medicine Neurology
 HSMN NewsFeed - 24 Jun 2020
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn(R) for the Treatment of Alzheimer's Disease
Regenerative Medicine Neurology
 HSMN NewsFeed - 27 May 2020
BrainStorm Appoints Pharmaceutical Veteran Stacy R. Lindborg, Ph.D. as Executive Vice President, Head of Global Clinical Research
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 28 Jun 2018
BrainStorm Strengthens Executive Management Team with the Appointment of Susan Ward, Ph.D. and Joseph Petroziello
Regenerative Medicine Personnel
 HSMN NewsFeed - 21 Mar 2018
BrainStorm Appoints Two Leading Thought Leaders in the Fields of Neuroscience and Regenerative Medicine to its Scientific Advisory Board
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 8 Mar 2018
BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017
Regenerative Medicine Neurology
 HSMN NewsFeed - 5 Feb 2018
BrainStorm Cell Therapeutics Appoints Senior Kite Executive, Anthony Polverino, Ph.D., to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 2 Nov 2017
BrainStorm Strengthens Executive Team: Appoints Eyal Rubin as Chief Financial Officer
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 16 Oct 2017
BrainStorm Enrolls First Patients in Phase 3 Trial of NurOwn(R) in ALS
Regenerative Medicine Neurology
 HSMN NewsFeed - 7 Aug 2017
BrainStorm Supports Commitment to ALS Patient Community with Appointment of a Vice President of Patient Advocacy and Government Affairs
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 25 Jul 2017
BrainStorm Announces Agreement with University of California Irvine Medical Center to Participate in Phase 3 Trial of NurOwn(R) in ALS
Regenerative Medicine Neurology
 HSMN NewsFeed - 21 Jul 2017
Brainstorm Awarded $16 Million Non-Dilutive Grant from CIRM in Support of Phase 3 Clinical Trial of NurOwn(R) in ALS
Regenerative Medicine Neurology
 HSMN NewsFeed - 18 Jul 2017
BrainStorm Announces Agreements with Mass. General Hospital and California Pacific Medical Center to Participate in Phase 3 Trial of NurOwn(R) in ALS
Regenerative Medicine Neurology
 HSMN NewsFeed - 6 Mar 2017
BrainStorm Strengthens Management Team with Appointment of Ralph Z. Kern, MD, MHSc as Chief Operating Officer and Chief Medical Officer
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 27 Feb 2017
BrainStorm Names Dr. June S. Almenoff and Arturo O. Araya to its Board of Directors as Company Prepares for Clinical and Commercial Success
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 21 Feb 2017
BrainStorm Seeking Approval To Distribute NurOwn(R) in Canada
Regenerative Medicine Neurology Regulatory Distribution
 HSMN NewsFeed - 7 Dec 2015
BrainStorm Cell Therapeutics Announces Appointment of Dr. Revital Geffen-Aricha as Vice President of Research & Development
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 3 Aug 2015
BrainStorm Strengthens Executive Team: Announces the Appointment of Yoram Bibring as Chief Financial Officer
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 25 Mar 2014
BrainStorm and Massachusetts General Hospital Sign Definitive Agreement for ALS Clinical Trial
Regenerative Medicine Neurology
 HSMN NewsFeed - 28 Jan 2013
BrainStorm Cell Therapeutics Appoints Alon Natanson as Chief Executive Officer
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 24 Jan 2011
BrainStorm Appoints Dr. Adrian Harel as Chief Operating Officer and Acting Chief Executive Officer
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 11 May 2010
BrainStorm Announces Significant Milestones Achieved and 2009 Review
Regenerative Medicine Neurology
 HSMN NewsFeed - 24 Aug 2009
BrainStorm Cell Therapeutics Secures Funding to Reach Clinical Trials for ALS
Regenerative Medicine Neurology
 HSMN NewsFeed - 2 Sep 2008
World Renowned ALS Expert From Harvard Medical School and Mass. General Hospital, Dr. Robert H. Brown Jr., Joins BrainStorm Cell Therapeutics Scientific Advisory Board
Regenerative Medicine Personnel
 HSMN NewsFeed - 12 Nov 2007
BrainStorm Cell Therapeutics Secures Significant Equity Financing and Raises Research Budget
Regenerative Medicine Neurology
 HSMN NewsFeed - 12 Oct 2007
Rami Efrati, Former VP Business Development and Marketing for NICE SYSTEMS' Government Division, Joins BrainStorm As CEO
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 8 Oct 2007
BrainStorm on the Verge of a Breakthrough Towards Developing a Cure for Lou Gehrig's Disease
Regenerative Medicine Neurology
 HSMN NewsFeed - 10 Sep 2007
BrainStorm Cell Therapeutics Takes Initial Steps Toward FDA Submission
Regenerative Medicine Neurology
 HSMN NewsFeed - 16 Jul 2007
BrainStorm Cell Therapeutics Elects Moshe Lion to Its Board of Directors
Regenerative Medicine Personnel
Return to NewsFeed  

 Additional items found! 3

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 3 additional stories matching:
BrainStorm Cell Therapeutics
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.